Literature DB >> 3584139

Structure of a tetrahedral transition state complex of alpha-chymotrypsin dimer at 1.8-A resolution.

A Tulinsky, R A Blevins.   

Abstract

A 1.8-A resolution x-ray crystallographic restrained least squares refinement has been carried out on the phenylethane boronic acid (PEBA) complex of alpha-chymotrypsin dimer (alpha-CHT), and it has been compared to the 1.67-A resolution structure of the native enzyme. PEBA has a high binding affinity for alpha-CHT, and the boronate forms a tetrahedral complex with Ser-195 OG of one molecule of the dimer; the boronate in the other molecule is severely disordered and does not form a tetrahedral complex. The former could be a model of the transition state of catalysis. The complex of PEBA X alpha-CHT displays significant nonequivalence in conformation of side chains between the independent molecules comparable to the native enzyme, but, like the latter, shows a high degree of fidelity in the folding of the main chain. The orientation of the phenyl ring, CA and CB of PEBA, in the specificity sites of the two molecules is similar, suggesting that recognition is fairly insensitive to small departures from local symmetry; the same does not apply to the boronate functionalities suggesting that greater precision is required for catalysis. The folding of the molecule remains the same upon PEBA binding, but some of the side chains respond nonequivalently. The latter is a consequence of the inherent nonequivalence of the native dimer and the asymmetrical nature of the PEBA binding.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3584139     DOI: 10.2210/pdb6cha/pdb

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Protonation linked equilibria and apparent affinity constants: the thermodynamic profile of the alpha-chymotrypsin-proflavin interaction.

Authors:  Gilles Bruylants; René Wintjens; Yvan Looze; Christina Redfield; Kristin Bartik
Journal:  Eur Biophys J       Date:  2007-04-19       Impact factor: 1.733

2.  Peptide modification by incorporation ofα-trifluoromethyl substituted amino acids.

Authors:  B Koksch; N Sewald; K Burger; H D Jakubke
Journal:  Amino Acids       Date:  1996-09       Impact factor: 3.520

3.  Crystal versus solution structure of enzymes: NMR spectroscopy of a peptide boronic acid-serine protease complex in the crystalline state.

Authors:  S Farr-Jones; S O Smith; C A Kettner; R G Griffin; W W Bachovchin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-keto-amide transition-state mimetic.

Authors:  R Krishnan; A Tulinsky; G P Vlasuk; D Pearson; P Vallar; P Bergum; T K Brunck; W C Ripka
Journal:  Protein Sci       Date:  1996-03       Impact factor: 6.725

5.  Combining flavin photocatalysis with parallel synthesis: a general platform to optimize peptides with non-proteinogenic amino acids.

Authors:  Jacob R Immel; Maheshwerreddy Chilamari; Steven Bloom
Journal:  Chem Sci       Date:  2021-06-30       Impact factor: 9.969

Review 6.  Molecular recognition with boronic acids-applications in chemical biology.

Authors:  Gillian F Whyte; Ramon Vilar; Rudiger Woscholski
Journal:  J Chem Biol       Date:  2013-06-01

7.  Synthetic analogues of chymostatin. Inhibition of chymotrypsin and Streptomyces griseus proteinase A.

Authors:  N P Tomkinson; I J Galpin; R J Beynon
Journal:  Biochem J       Date:  1992-09-01       Impact factor: 3.857

8.  Inhibition of chymotrypsin by a complex of ortho-vanadate and benzohydroxamic acid: structure of the inert complex and its mechanistic interpretation.

Authors:  Aaron Moulin; Jason H Bell; R F Pratt; Dagmar Ringe
Journal:  Biochemistry       Date:  2007-05-01       Impact factor: 3.162

9.  An introduction to boron: history, sources, uses, and chemistry.

Authors:  W G Woods
Journal:  Environ Health Perspect       Date:  1994-11       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.